The Steve Jackson Laboratory Website
Transformative discoveries in genome and cellular integrity


Lab Announcements and Industry News

AZ moves closer to Lynparza filing in breast cancer

AZ have announced that they are closer to Lynparza (olaparib) being licensed for the treatment of breast cancer. Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy. This is the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.

Read More
2017Kate Dry